KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Finished Goods (2018 - 2020)

Historic Finished Goods for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q1 2020 value amounting to $222.2 million.

  • Amneal Pharmaceuticals' Finished Goods changed N/A to $222.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $222.2 million, marking a year-over-year change of. This contributed to the annual value of $150.7 million for FY2019, which is 3192.81% down from last year.
  • As of Q1 2020, Amneal Pharmaceuticals' Finished Goods stood at $222.2 million.
  • In the past 5 years, Amneal Pharmaceuticals' Finished Goods registered a high of $222.2 million during Q1 2020, and its lowest value of $150.7 million during Q4 2019.
  • Moreover, its 3-year median value for Finished Goods was $194.8 million (2018), whereas its average is $190.6 million.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' Finished Goods was 3192.81% (2019), while the steepest drop was 3192.81% (2019).
  • Amneal Pharmaceuticals' Finished Goods (Quarter) stood at $221.4 million in 2018, then tumbled by 31.93% to $150.7 million in 2019, then surged by 47.4% to $222.2 million in 2020.
  • Its Finished Goods stands at $222.2 million for Q1 2020, versus $150.7 million for Q4 2019 and $168.2 million for Q3 2019.